A randomized, open-label study assessing safety, tolerability and efficacy of an induction-maintenance treatment strategy including lopinavir/ritonavir plus tenofovir disoproxil fumarate and emtricitabine [emtricitabine/tenofovir disoproxil fumarate] versus efavirenz plus tenofovir disoproxil fumarate and emtricitabine in antiviral-naive HIV-1/HCV [hepatitis C virus] co-infected subjects

Trial Profile

A randomized, open-label study assessing safety, tolerability and efficacy of an induction-maintenance treatment strategy including lopinavir/ritonavir plus tenofovir disoproxil fumarate and emtricitabine [emtricitabine/tenofovir disoproxil fumarate] versus efavirenz plus tenofovir disoproxil fumarate and emtricitabine in antiviral-naive HIV-1/HCV [hepatitis C virus] co-infected subjects

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2013

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 15 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top